Correlation Between Eugene Investment and AptaBio Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eugene Investment and AptaBio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eugene Investment and AptaBio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eugene Investment Securities and AptaBio Therapeutics, you can compare the effects of market volatilities on Eugene Investment and AptaBio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eugene Investment with a short position of AptaBio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eugene Investment and AptaBio Therapeutics.

Diversification Opportunities for Eugene Investment and AptaBio Therapeutics

0.78
  Correlation Coefficient

Poor diversification

The 3 months correlation between Eugene and AptaBio is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Eugene Investment Securities and AptaBio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AptaBio Therapeutics and Eugene Investment is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eugene Investment Securities are associated (or correlated) with AptaBio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AptaBio Therapeutics has no effect on the direction of Eugene Investment i.e., Eugene Investment and AptaBio Therapeutics go up and down completely randomly.

Pair Corralation between Eugene Investment and AptaBio Therapeutics

Assuming the 90 days trading horizon Eugene Investment Securities is expected to under-perform the AptaBio Therapeutics. In addition to that, Eugene Investment is 1.14 times more volatile than AptaBio Therapeutics. It trades about -0.51 of its total potential returns per unit of risk. AptaBio Therapeutics is currently generating about -0.32 per unit of volatility. If you would invest  811,000  in AptaBio Therapeutics on September 1, 2024 and sell it today you would lose (159,000) from holding AptaBio Therapeutics or give up 19.61% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Eugene Investment Securities  vs.  AptaBio Therapeutics

 Performance 
       Timeline  
Eugene Investment 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eugene Investment Securities has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
AptaBio Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Eugene Investment and AptaBio Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eugene Investment and AptaBio Therapeutics

The main advantage of trading using opposite Eugene Investment and AptaBio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eugene Investment position performs unexpectedly, AptaBio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AptaBio Therapeutics will offset losses from the drop in AptaBio Therapeutics' long position.
The idea behind Eugene Investment Securities and AptaBio Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance